2Mackay K, Kondaiah P, Danielpour, et al. Expression of transforming growth factor- beta 1 and beta 2 in rat glomeruli. Kidney Int, 1990,38(6):1095- 1100.
6Iwano M, Kubo A, Nishino T, et al. Quantification of glomerular TGF - beta1 Mrn in patients with diabetesmellitus. Kidney Int, 1996,49(4) : 1120 - 1126.
7Studer RK, Negrete H, Craven PA, et al. Protein kinase C signals thromboxane induced increases in fibronectin synthesis and bioactivity in mesangial cells. Kidney Int, 1995,48 (2) : 422 - 430.
8Ziyadeh FN, Isono M, Chen S. Involvement of the transforming growth factor- β system in the pathogenesis of diabetic nephropathy. Clin Exp Nephrol, 2002,6:125 - 129.
9Ziyadeh FN,Han DC. Involvement of transforming growth factor - beta and its receptors in the pathogenesis of diabetic nephrology. Kidney Int, 1997,60 (Suppl) : 7 - 11.
10Ha SW, Kim HJ,Bae JS, et al. Elevation of urinary betaig- h3, transforming growth factor - beta induced protein in patients with type2 diabetes and nephropathy. Diabetes Res Clin Pract,2004,65(2) : 167 - 173.
3[2]Wolf G. Link between angiotensin II and TGF-β in the kidney.Miner Elect rolyte Metab, 1998,24:174-180
4[3]Sharma K, Ziyadeh FN.Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-β as a key mediator.Diabetes, 1995,44:1139-1146
5[4]Shankland SJ, Scholey JW Ly H, et al. Expression of transforming growth factor-β1 during diabetic renal hypertrophy. Kidney Int, 1994,46:430-442
6[5]Ruilope LM.Renoprotection and renin-angiotensin system blockade in diabetes mellitus. Am J Hypertensions, 1997,10:325S-331S
7[6]Califf RM, Cohn JN. Cardiac protection: evolving role of angiotensin receptor blockers. AmHeartJ, 2000,139:S15-22
8[7]UrataH, Strobel F, Strobel, Ganten D. Widespread tissue distribution of human chymase. J Hypertens, Supp1 1994,12:S17-S22
9Wang W,Koka V,Lan HY.Transforming growth factor-beta and Smad signalling in kidney diseases.Nephrology (Carlton),2005,10(1):48-56.
5Tervaert T W, Mooyaart A L, Amann K, et al. Pathologic classi-fication of diabetic nephropathy[ J ]. J Am Soc Nephrol ,2010 ,21 (4) :556-63.
6Yuan W J, Jia F Y, Meng J Z. Effects of genistein on secretion of extracellular matrix components and transforming growth factor beta in high-glucose-cultured rat mesangial cells[ J]. J Art/f Or- gans ,2009,12 (4) :242-246.
7Li X, Hu J, Zhang Q, et al. Urocortin 1 improves renal function in rats with streptozotocin-induced diabetes by inhibiting overpro- duction of TGF-betal and VEGF[ J]. Br J Pharmacol,2009,157 (6) :994-1003.
8Athyros V G, Mitsiou E K, Tziomalos K, et al. Impact of man- aging atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy[J]. Expert Opin Pharma- cother,2010,11 (5) :723-730.
9Hills C E, Squires P E. TGF-beta 1 induced epithelial to mesen- ehymal transition and therapeutic intervention in diabetic ne- phropathy[ J]. Am J Nephrol,2010,31 ( 1 ) :68-74.
10Nakanmm J, FukuiM, EbibaraI, et al. MRNA expression of growthfactors in glomerularti'om diabetic rats[ J ] .Diabetes, 1993, 42 ( 3 ): 450-456.
